Investor Alert

New York Markets Open in:

Market Pulse Archives

Feb. 19, 2021, 7:48 a.m. EST

J&J submits application for its COVID-19 vaccine to the WHO

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Johnson & Johnson (JNJ)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Johnson & Johnson /zigman2/quotes/201724570/composite JNJ -1.15% gained 0.4% in premarket trading on Friday after the company said it had submitted an application for its experimental single-dose COVID-19 vaccine to the World Health Organization for emergency authorization. Obtaining an emergency-use listing from the WHO allows J&J's vaccine candidate to be made available through Covax, a global consortium supplying COVID-19 vaccines to lower-income countries. J&J's vaccine, which has not yet been authorized for use in the U.S., is set to be reviewed by a group of vaccine experts next week as part of the Food and Drug Administration's regulatory process. The company also submitted a regulatory application for its coronavirus vaccine in the European Union on Feb. 15. J&J's stock is up 11.3% over the past year, while the S&P 500 /zigman2/quotes/210599714/realtime SPX +0.28% is up 16.3%.

/zigman2/quotes/201724570/composite
US : U.S.: NYSE
$ 162.97
-1.90 -1.15%
Volume: 14.09M
Jan. 24, 2022 4:00p
P/E Ratio
24.36
Dividend Yield
2.60%
Market Cap
$434.04 billion
Rev. per Employee
$679,695
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,410.13
+12.19 +0.28%
Volume: 3.89B
Jan. 24, 2022 5:04p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.